Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/18957
Title: | Antibody-Drug Conjugates for Cancer Therapy. | Austin Authors: | Parslow, Adam C;Parakh, Sagun ;Lee, Fook-Thean;Gan, Hui K ;Scott, Andrew M | Affiliation: | Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia Department of Medical Oncology, Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia Department of Medicine, University of Melbourne, Melbourne 3010, Australia |
Issue Date: | 11-Jul-2016 | Date: | 2016-07-11 | Publication information: | Biomedicines 2016; 4(3): E14 | Abstract: | Antibody-drug conjugates (ADCs) take advantage of the specificity of a monoclonal antibody to deliver a linked cytotoxic agent directly into a tumour cell. The development of these compounds provides exciting opportunities for improvements in patient care. Here, we review the key issues impacting on the clinical success of ADCs in cancer therapy. Like many other developing therapeutic classes, there remain challenges in the design and optimisation of these compounds. As the clinical applications for ADCs continue to expand, key strategies to improve patient outcomes include better patient selection for treatment and the identification of mechanisms of therapy resistance. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/18957 | DOI: | 10.3390/biomedicines4030014 | ORCID: | 0000-0003-3891-2489 0000-0002-6656-295X |
Journal: | Biomedicines | PubMed URL: | 28536381 | ISSN: | 2227-9059 | Type: | Journal Article | Subjects: | ADC antibody–drug conjugate cancer immunotherapy monoclonal antibodies resistance |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.